Prognostic Features in Intermediate‐Size Supraglottic Tumors Treated With Open Supraglottic Laryngectomy

xlomafota13 shared this article with you from Inoreader Prognostic Features in Intermediate‐Size Supraglottic Tumors Treated With Open Supraglottic Laryngectomy Via The Laryngoscope Objectives/Hypothesis We investigated growth patterns and pathological features in intermediate‐size laryngeal carcinoma amenable to supraglottic laryngectomy. Study design Retrospective cohort study. Methods We reviewed patients who underwent an open partial horizontal laryngectomy (OPHL) type I. We analyzed pathological data, tumor sizes, overall survival, disease‐specific survival, local control, and laryngeal preservation. Results were stratified between three groups: group I comprised patients with endolaryngeal carcinoma, group II comprised patients with anterior epilaryngeal carcinoma who underwent an OPHL type I + base of tongue (BOT), group III comprised patients with lateral epilaryngeal carcinoma who underwent an OPHL type I + pyriform sinus (PIR). Results Sixty‐eight patients were analyzed. The 5‐year rates of overall survival, disease‐specific survival, local control, and laryngeal preservation were 68.4%, 83.7%, 91.6%, and 98.3%, respectively. The tumor sizes at pathological examination were similar between the three groups (mean 27 mm, P = .80) and were associated with pathological features, notably pre‐epiglottic space (PES) invasion (24.9 mm vs. 32.2 mm, P = .01), occult invaded lymph nodes (22.6 mm vs. 29.9 mm, P = .03), and trends for margins status (26.5 mm vs. 29.3 mm, P = .45). The risks of PES invasion, occult lymph nodes, and positive margins, respectively, predominated in group I (41.7%), group II (56.3%), and group III (23.3%). Conclusion In intermediate‐size tumors amenable to supraglottic laryngectomy, pathological features are associated with tumor size according to group stratification based on tumor location. Level of Evidence 4 Laryngoscope, 131:E1980–E1986, 2021 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.